killed any positive movement today, page-29

Hi pattyp77, after PRR goes through the Phase III trial and then we could say PRR should be a quality in biotech sector since you could assess the value with some trustable margin.

I don't think anyone could evaluate PRR correctly since if it succeeds in Phase III trial, it could have billions dollar market cap but if it fails it could be nothing again. I call this kind of features as breakers.

If you follow the normal value evaluation ways as you work as a value investor, you would be wrong and surprised. I play the pennies by buying at extremely, selling after shooting up normal, but betting if I could see the breakers are there and could be triggered at any time.

I bet on a series of breakers along the way that PRR tries to commercialize its CVac not anything else. I bet until the results I could know and understand.

At moment I bet on DNDN success since it is a event to declare a new era potentially. PRR would be directly benefited by this success since DNDN has clean up the pathway for PRR success.

To me I take the new capital as little to affect PRR's future value. I bet on for the dollars and would like to pay the cost to get the dollars. If I could not get the dollars, it is what I deserve and I would accept the consequence.

We need the gut, the faith, the vision, never distracting by the blips, and some lucks for dollars.